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Spotlight on Cancer Informatics is a new feature 
of Cancer Informatics designed to help build a 
sense of community among informatics researchers 
attempting to at once provide informatics services 
to cancer studies while simultaneously conducting 
independent research that leads to advances in 
informatics solution. Individuals are “Spotlighted” 
at the invitation of the Editor-in-Chief. To be 
considered for an invitation, please send a brief 
description of your research interests to caninfo@
la-press.com along with your curriculum vitae.
Q 
What would you say is the primary focus of 
your research effort (how do you refer to your 
‘sub-area’)?
A 
The primary focus of my group’s research is 
developing, validating, applying and automat-
ing  algorithms for decision support and discovery 
for molecular medicine. The emphasis is on can-
cer; however, the methods are broad enough to be 
useful for a number of other diseases, as well as 
for general pattern recognition and discovery 
tasks.
One set of these algorithms is designed to produce 
models for diagnosis, clinical outcome prediction and personalized treatment decisions. Another set is 
designed to select compact sets of biomarkers. Finally the last set seeks to discover structural relation-
ships (e.g., gene regulatory networks and protein-protein or gene-protein interaction networks) to shed 
light on complex molecular mechanisms of disease.
Q 
What do you consider to be the most signiﬁ  cant open questions and research challenges in cancer 
informatics?
A 
There exist numerous challenges of which I mention just a few: Overﬁ  tting and other data analysis 
problems caused by very small samples and large dimensionalities. Developing mechanistic 
(causative) models and separating them from purely predictive ones. Utilizing a multiplicity of 
information/data types concurrently, for example mass throughput, clinical, imaging, literature, data 
etc. There is a need for - but lack of standards in - data analysis for mass throughput data. Biologists, 
physicians and informatics researchers often do not share the same language, scientiﬁ  c culture, and 
expectations. There are serious assay reproducibility issues. It is not clear how to optimally deliver 
the results of molecular medicine to physicians at the bedside. Regulating molecular medicine 
modalities for safety without impeding timely progress in the ﬁ  eld is a big challenge. Exploring 
proper ways to build and maintain interdisciplinary teams and assign academic credit is another. 
Finally there is a myriad of thorny ethical issues surrounding the storage, protection, and retrieval of 
patient data.
Q 
What do you consider to be the most signiﬁ  cant developments arising from research in cancer 
informatics?
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A 
The emerging ability to perform early diagnosis, personalize treatments, predict clinical outcomes, 
and understand disease using mass-throughput information.
Q 
Tell us about your collaborative research. How much of your effort is typically focused on helping 
to provide cancer researchers with clinically signiﬁ  cant results?
A 
Approximately 50% of my work is application of methods and analysis of data for cutting edge 
biomedical (mainly cancer) research. The rest is methods development, service, and teaching, 
which I hope to also beneﬁ  t cancer researchers down the road.
Q 
Do you ﬁ  nd balancing all of these activities challenging? How might cancer centers better meet 
the increasing demand for the analysis of high-dimensional data?
A 
It is very challenging as often methods are not well-developed and method development has to 
take place during the lifecycle of the speciﬁ  c cancer research project, subject to many practical 
constraints (time, resources, etc.). Furthermore, when a good method is developed, in the initial 
phases of its lifecycle its application is often not straightforward unless the inventor is involved, which 
in turn precludes scaling-up of the method development efforts and dissemination of the methods 
rapidly.
There is a number of ways to meet these needs:
  –    Developing a critical mass of dedicated experts inside the institution and solid working 
collaborations with experts in other institutions.
  –    Creating dedicated groups to develop, test, and automate new methods (an example methods 
group is the Discovery Systems Laboratory at Vanderbilt) as well as groups that apply appropriate 
methods and protocols for analysis in research (such a group is the High-Dimensionality Core 
at the Vanderbilt Ingram Cancer Center).
  –   Creating consulting services (e.g., the “Omics” clinic organized jointly by the Dpts of Biostatistics 
and Biomedical Informatics at Vanderbilt) that will disseminate methodological knowledge and 
connect cancer biology researchers with methods researchers according to the project needs.
  –    Creating and sharing robust analysis protocols and automated data analysis systems, and code 
libraries (e.g., the GEMS system for gene expression analysis and the Causal Explorer system 
for biomarker and regulatory network discovery).
Q 
What do you consider to be the most pressing challenges or barriers to success in the ﬁ  eld of cancer 
research?
A 
Cancer is a hugely heterogeneous class of diseases that affect cells and organisms in numerous 
concurrent ways both at the molecular level and at the system level. Thus developing methods to 
help us understand the pathophysiology of cancer is particularly challenging.
Q 
What do you consider to be the most signiﬁ  cant developments or advancements arising from cancer 
research?
A 
Same as previously stated: the emerging ability to perform early diagnosis, personalize treatments, 
predict clinical outcomes, and understand disease using mass-throughput information.
Q 
When did you decide to be—or realize that you were—involved primarily in informatics as a 
research focus?
A 
In 1985 when I started intensive informatics research while in medical school, and then in 1991 
when I entered a PhD program with this speciﬁ  c focus.
Q 
Do you currently conduct research on diseases other than cancer?5
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A 
My work is inherently methodological and as such applies to many diseases. For example, we have 
been building models with colleagues to predict lab results across the board for all Vanderbilt 
inpatient population. In the past I have worked on predicting mortality in pneumonia patients, graft 
failure in post-transplant patients, mortality in patients with syncope, to classify biomedical literature 
in internal medicine, etc.
Q 
Tell us about three or four ‘must-have’ essential informatics computing or research resources that 
you use on a regular basis developed by someone other than yourself or collaborators. Why are 
these resources so useful, and why do you consider them essential?
A 
Matlab, because it facilitates very rapid prototyping of code and allows one to focus on the algo-
rithm instead of the language.
The internet through which access to numerous remote sources of knowledge, tools, and colleagues is 
facilitated.
A collection of library sources very conveniently accessed in the Eskind Biomedical Library building 
where Vanderbilt’s Department of Biomedical Informatics is housed.
The last two resources are essential because methods work needs to be grounded very solidly on the 
vast literature (past and present) on computational, mathematical, statistical, and biochemical/medical/
biological research and tools. The ﬁ  rst resource is essential because it allows a quick transition from 
the paper/whiteboard to actual experiments and data modeling.
Q 
What do you think about the development of open access publishing and open access development? 
How has either changed your perspective on research and development practices?
A 
I can see both advantages and disadvantages in these paradigms relative to older and more estab-
lished ones. Open access publishing gives easier and faster access to new knowledge to some 
members of the community. On the other hand the publishing costs may be prohibitive to some author 
groups (especially so outside the US and the more industrialized nations). Open access development is 
leveraged by low-cost and for gratis coding, however for areas where technology is not mature this may 
lead to dangerous errors in the software for which there is no accountability. This is especially trouble-
some for medical and for security-sensitive applications (e.g., biosurveillance). Time will tell whether 
these models are successful. Neither has affected my own work directly so far.
Q 
What books do you think should be required reading for researchers involved in informatics? In 
cancer research?
A 
The list is very wide, I will mention a few books that I open or cite frequently. In the ﬁ  eld of 
informatics: Cormen et al’s “Introduction to algorithms”, Agresti’s “Categorical data analysis”, 
and Spirtes et al’s “Causation, Prediction and Search” are books that I visit and cite again and again. 
Mitchell’s “machine learning” gives a clear (but dated nowadays) introduction to the ﬁ  eld, Duda et al’s 
“Pattern Classiﬁ  cation” is an excellent textbook and reference, while Herbrich’s “Learning Kernel 
Classiﬁ  ers” is probably the single most useful SVM textbook and reference in my bookshelf.
With respect to the ﬁ  eld of cancer research, please note that I am conducting methodological research and 
not biological so my perspective here is certainly skewed compared to the cancer biologist’s. With this 
caveat stated, I have found “Molecular Biology of the Cell” (Alberts et al), Genes VII (Lewin, currently 
in the VIIIth edition), and Liebler’s “Introduction to Proteomics” very valuable. Very readable—and 
brief—ﬁ  rst introductions to cancer molecular medicine for interdisciplinary scientists are Ross’ “Introduc-
tion to Oncogenes and molecular cancer medicine” as well as Ross’ “Introduction to molecular medicine”. 
Redei’s “Encyclopedic Dictionary of Genetics, Genomics and Proteomics” is a worthy encyclopedic 
reference.
Q 
What books are on your current reading list?6
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A 
Many, but I am currently focusing on large parts of Tietz’s Clinical Chemistry and Molecular 
Diagnostics. (http://www.harcourt-international.com/catalogue/title.cfm?ISBN=0721601898)
Q 
Do you teach any courses? If so which ones?
A 
I teach Biomedical Artiﬁ  cial Intelligence and Machine Learning at the graduate level as well as 
an advanced lab component associated with that course. I also have given directed studies in 
AI/ Machine Learning and Information retrieval and several seminars and tutorials. I am also on the 
teaching faculty of the Cancer Biology and Clinical Proteomics graduate-level courses at 
Vanderbilt.
Q 
List the historical research ﬁ  gures that you think have most inﬂ  uenced how you think about 
research? Why are these inﬂ  uences signiﬁ  cant?
A 
Many great scientists have inﬂ  uenced my reasoning and have qualities that I admire. I will men-
tion a few. Collectively the ancient Greek scientists were amazing in their ability to exceed the 
standard of science at the time: for example they computed the circumference of the earth, computed 
distances between the earth and the sun, laid the foundations of geometry and logic etc. etc.
Jumping ahead a couple of millenia, Niels Bohr was very inﬂ  uential to me because he did not emphasize 
whether the data were consistent with his biases: as long as the theory (e.g., Copenhagen interpretation 
of quantum mechanics) was validated experimentally, he accepted it despite it being vastly counter-
intuitive. Einstein despite all his brilliance was not able to leap mentally that far and insisted (wrongly) 
on determinism.
David Hume was incredibly powerful intellectually and personality-wise in recognizing and describing 
the limits of both faith-based doctrines and inductive science. He practically destroyed them both from 
a philosophical perspective and lived to be happy regardless. Reichenbach is inspiring because he 
provided, in my assessment, a simple but very convincing account of why we can still pursue inductive 
generalization successfully despite Hume being correct.
Karl Marx and Adam Smith laid out two still dominant economic frameworks and identiﬁ  ed major 
principles of human economic behaviour. Aristotle and DaVinci were inspiring on account of their 
breadth and depth of knowledge. Chomsky is inspiring in his dual ability as linguist and contrarian 
political scientist with deep humanitarian concerns.
Darwin’s colossal mental leap, as well as his meticulous method toward establishing evolution, are 
astounding. Richard Feynman was inspiring in his balance of scientiﬁ  c ability as well as ability to be 
a well-adjusted man. He also was one of the clearest thinkers ever to live: his “Lectures on physics” 
are the clearest science book I have come across so far. Bertrand Russell was inspiring because of his 
momentous achievement in the meta-theory of mathematics but also because at the same time he was 
committed to humanitarian values and chose to be imprisoned rather than betray them. On the side he 
won a Nobel prize for literature. Similarly Herb Simon won a Nobel prize in economics but did most 
of his work on computer science/artiﬁ  cial intelligence, and political science.
With respect to my own research area, Gregory F. Cooper my former advisor and mentor introduced 
me to rigorous, principled and uncompromised research. He also taught me Bayesian networks and 
computational causal discovery, among other topics. Judea Perl, Peter Spirtes, Clark Glymour, Granger, 
and Cooper are among the major pioneers of modern computational causal discovery. These researchers 
have collectively shaped a very powerful paradigm for discovery using computational tools and this 
collective achievement will prove to be no less signiﬁ  cant in my opinion than many of the highest 
achievements of science so far.
Q 
Could you describe for us brieﬂ  y what key insights you think researchers in the area of causal 
discovery have provided that make modern computational causal discovery so exciting to you?7
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A 
The main insights are:
  –    Causation is a crucial aspect of discovery and has to be addressed explicitly when thinking 
about research and data collection/analysis.
  –    There is a formal framework that ties together causation and prediction.
  –    Randomized experiments are not always feasible, ethical, efﬁ  cient or even correct for 
discovering causality.
  –    It is mathematically and algorithmically possible to learn causal relationships from observa-
tional data or mixtures of observational and experimental data.
  –    It is mathematically and algorithmically possible to discover structural confounding (i.e., 
induce correct causal structure in the presence of hidden (i.e., unmeasured) variables)).
  –    Although causal discovery is worst-case intractable, there exist algorithmic techniques and 
reasonable assumptions to make it tractable in practical settings.
Q 
Which research meetings do you attend on a regular basis? Please provide URL’s any other infor-
mation you consider relevant.
A 
I almost never miss the AMIA Fall meeting (www.amia.org). Occasionally I go—or at least send 
papers—to AAAI (www.aaai.org/Conferences/ National/2006/aaai06.html), ISMB (ismb2006.cbi.
cnptia.embrapa.br/), ICML (www.icml2006.org/icml2006/14770.html), KDD (www.kdd2006.com/), 
AI and Stats (www.gatsby.ucl.ac.uk/aistats/), FLAIRS (www.indiana.edu/~ﬂ  airs06/), MEDINFO (www.
medinfo2007.org/), and UAI (www.ics.uci.edu/~csp/uai2006/).
Q 
Please tell us about your own resource development efforts. Which of your computing resources 
or research papers would you like most people to know about?
A 
Currently, the Markov Blanket & Bayesian Network discovery algorithms such as HITON and 
MMHC for biomarker discovery and structural discovery. Related papers and code can be found 
in the DSL web site: www.dsl-lab.org. Another is the GEMS system for gene expression modelling 
and biomarker discovery; papers and code are available from the DSL web site. Another one is the 
Causal Explorer toolkit for causal discovery and biomarker discovery (code also available from www.
dsl-lab.org).
Q 
If you could change three things about how informatics research is conducted, used, perceived, or 
resourced, what would they be?
A 
First, Increase the realization that informatics is less about computers and more about methods. 
Second, rigorous training in biomedicine and computer science, math, and statistics is essential for 
the advancement of the ﬁ  eld. Third, informatics is not just an enabling technology but a ﬁ  eld that 
contributes important novel methods for discovery.
Q 
  What do you think are the most signiﬁ  cant cancer research studies in the last year that have been 
made possible by advances in informatics? Do you have any that speciﬁ  cally stick out in your 
mind as breakthroughs?
A 
It is very difficult to make a “most significant” determination for breakthrough clinical 
and research studies before seeing longer-term clinical impact and citation impact respectively. 
Moreover, in a sense, all papers were made possible by advances in informatics: regardless of study, 
it is safe to assume that samples were assayed by computer-controlled machinery, resulting data was 
analyzed with statistical and pattern recognition software, and results were indexed/stored/retrieved, 
and published electronically. It is also more than probable that hypotheses were shaped by consulting 8
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databases containing bibliographic, sequence, functional, evolutionary, genetic and other stored 
knowledge.
In terms of excellent—but certainly not “most signiﬁ  cant”—speciﬁ  c examples of papers using informatics 
for cancer research, I could mention include “Gene Expression Tests Foretell Breast Cancer's Future,” 
Ken Garber, Science 19 March 2004: Vol. 303. no. 5665, pp. 1754 - 1755. This report and the prior 
research leading to it, is an exciting example of clinical bioinformatics-enabled service that is offered 
to the public and that has the potential to revolutionize care for cancer patients (by predicting metasta-
ses in breast cancer patients and helping treatment decisions).
As a highly-regarded example of array technology enabling discovery of new and signiﬁ  cant biological 
insights about cancer I can mention Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, 
Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, Depinho RA, Chin L, Elledge SJ. “A Genetic 
Screen For Candidate Tumor Suppressors Identiﬁ  es REST.” Cell. 2005 Jun 17;121(6):837-48.